Literature DB >> 30031182

Adjunctive Gamma Knife Surgery or Wait and Scan Policy After Optimal Resection of Large Vestibular Schwannomas: Clinical and Radiologic Outcomes.

Lucas Troude1, Mohamed Boucekine2, Marion Montava2, Jean-Pierre Lavieille2, Jean-Marie Régis2, Pierre-Hugues Roche2.   

Abstract

OBJECTIVES: Patients with large vestibular schwannomas (VSs) will require surgical treatment owing to the potential consequences of long tract and cranial nerve compression. We assessed the long-term clinical and radiologic outcomes of patients harboring large VSs treated with a facial nerve (FN)-sparing technique.
METHODS: We performed a single-center retrospective cohort study of 169 consecutive large VSs treated surgically from January 2003 to May 2015. The postoperative volume of the tumor residue was assessed using thin-slice magnetic resonance imaging 6 months after surgery. Postoperatively, the patients were allocated to a wait and rescan (W&reS) or an upfront gamma knife surgery (GKS) policy.
RESULTS: At the last follow-up examination, FN function was good (House-Brackmann grade I or II) in 84% of the patients. Of the 169 patients, 11% had undergone gross total resection, 59% near total, 21% subtotal, and 9% partial resection. In the 143 patients without gross total resection, the overall median tumor residue volume was 0.39 cm3. Of these 143 patients, 66 had been allocated to the W&reS policy and 77 to upfront GKS. Overall tumor control was achieved in 83% of cases, with a mean follow-up of 62 months. Of the 27 growing residues, 17 required salvage treatment (11% failure rate). The 1-, 5-, and 7-year progression-free survival rate was 95%, 82%, and 76% in the W&reS group and 99%, 81%, and 78% in the GKS group, respectively (P = 0.57).
CONCLUSIONS: Functional nerve-sparing resection provides satisfactory FN preservation. The low probability of long-term regrowth of small remnants is an argument for a W&reS protocol. GKS is a legitimate option for salvage treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Facial nerve; Gamma knife surgery; Large vestibular schwannoma; Subtotal resection; Tumor control; Tumor recurrence; Volume measurement

Mesh:

Year:  2018        PMID: 30031182     DOI: 10.1016/j.wneu.2018.07.093

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Facial Nerve Function After Microsurgical Resection in Vestibular Schwannoma Under Neurophysiological Monitoring.

Authors:  Felix Arlt; Johannes Kasper; Dirk Winkler; Katja Jähne; Michael Karl Fehrenbach; Jürgen Meixensberger; Caroline Sander
Journal:  Front Neurol       Date:  2022-05-24       Impact factor: 4.086

2.  Case Report: Extensive Temporal Bone Invasion in a Giant Vestibular Schwannoma.

Authors:  Fang Lyu; Jinlu Gan; Haijun Wang; Hongyang Zhao; Lei Wang; Fangcheng Zhang
Journal:  Front Surg       Date:  2022-05-25

3.  Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base section.

Authors:  Daniele Starnoni; Lorenzo Giammattei; Giulia Cossu; Michael J Link; Pierre-Hugues Roche; Ari G Chacko; Kenji Ohata; Majid Samii; Ashish Suri; Michael Bruneau; Jan F Cornelius; Luigi Cavallo; Torstein R Meling; Sebastien Froelich; Marcos Tatagiba; Albert Sufianov; Dimitrios Paraskevopoulos; Idoya Zazpe; Moncef Berhouma; Emmanuel Jouanneau; Jeroen B Verheul; Constantin Tuleasca; Mercy George; Marc Levivier; Mahmoud Messerer; Roy Thomas Daniel
Journal:  Acta Neurochir (Wien)       Date:  2020-07-29       Impact factor: 2.216

4.  The behavior of residual tumors following incomplete surgical resection for vestibular schwannomas.

Authors:  Hun Ho Park; So Hee Park; Hyeong-Cheol Oh; Hyun-Ho Jung; Jong Hee Chang; Kyu-Sung Lee; Won Seok Chang; Chang-Ki Hong
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

5.  Surgery After Surgery for Vestibular Schwannoma: A Case Series.

Authors:  Łukasz Przepiórka; Przemysław Kunert; Wiktoria Rutkowska; Tomasz Dziedzic; Andrzej Marchel
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.